These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


176 related items for PubMed ID: 3163271

  • 1. Metabolism, incorporation into DNA, and interactions with 1-beta-D-arabinofuranosylcytosine of 5-hydroxymethyl-2'-deoxyuridine in human promyelocytic leukemia cells (HL-60).
    Vilpo JA, Vilpo LM.
    Cancer Res; 1988 Jun 01; 48(11):3117-22. PubMed ID: 3163271
    [Abstract] [Full Text] [Related]

  • 2. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
    Grant S, Bhalla K, Rauscher F, Cadman E.
    Cancer Res; 1983 Nov 01; 43(11):5093-100. PubMed ID: 6577943
    [Abstract] [Full Text] [Related]

  • 3. Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA.
    Grant S, Jarvis WD, Swerdlow PS, Turner AJ, Traylor RS, Wallace HJ, Lin PS, Pettit GR, Gewirtz DA.
    Cancer Res; 1992 Nov 15; 52(22):6270-8. PubMed ID: 1423273
    [Abstract] [Full Text] [Related]

  • 4. Effects of 1-beta-D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution.
    Ross DD, Chen SR, Cuddy DP.
    Cancer Res; 1990 May 01; 50(9):2658-66. PubMed ID: 2328491
    [Abstract] [Full Text] [Related]

  • 5. Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.
    Grant S, Turner AJ, Bartimole TM, Nelms PA, Joe VC, Jarvis WD.
    Oncol Res; 1994 May 01; 6(2):87-99. PubMed ID: 7949469
    [Abstract] [Full Text] [Related]

  • 6. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K, Nayak R, Grant S.
    Cancer Res; 1984 Nov 01; 44(11):5029-37. PubMed ID: 6091869
    [Abstract] [Full Text] [Related]

  • 7. Schedule-dependent enhancement of 1-beta-D-arabinofuranosylcytosine incorporation into HL-60 DNA by deoxyguanosine.
    Ross DD, Akman SA, Joneckis CC, Yang E, Bachur NR.
    Cancer Res; 1984 Apr 01; 44(4):1530-5. PubMed ID: 6584206
    [Abstract] [Full Text] [Related]

  • 8. Induction of deoxycytidine kinase by 5-azacytidine in an HL-60 cell line resistant to arabinosylcytosine.
    Kong XB, Tong WP, Chou TC.
    Mol Pharmacol; 1991 Feb 01; 39(2):250-7. PubMed ID: 1705001
    [Abstract] [Full Text] [Related]

  • 9. Potentiation of cytotoxicity of 1-beta-D-arabinofuranosylcytosine for K562 human leukemic cells by cadeguomycin.
    Suzuki H, Kim SH, Tanara M, Okazaki K, Okabe T, Wu RT, Tanaka N.
    Cancer Res; 1987 Feb 01; 47(3):713-7. PubMed ID: 3467840
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
    Nandy P, Lien EJ, Avramis VI.
    Anticancer Res; 1999 Feb 01; 19(3A):1625-33. PubMed ID: 10470093
    [Abstract] [Full Text] [Related]

  • 11. Effect of the interval between exposures to cytarabine on its cytotoxic action on HL-60 myeloid leukemic cells.
    Leclerc JM, Momparler RL.
    Cancer Treat Rep; 1984 Sep 01; 68(9):1143-8. PubMed ID: 6592037
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of cell-killing effects of 1-beta-D-arabinofuranosylcytosine and daunorubicin by a new computer-controlled in vitro pharmacokinetic simulation system.
    Kishi S, Goto N, Nakamura T, Ueda T.
    Cancer Res; 1999 Jun 01; 59(11):2629-34. PubMed ID: 10363985
    [Abstract] [Full Text] [Related]

  • 13. Role of dephosphorylation in accumulation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in human lymphoblastic cell lines with reference to their drug sensitivity.
    Abe I, Saito S, Hori K, Suzuki M, Sato H.
    Cancer Res; 1982 Jul 01; 42(7):2846-51. PubMed ID: 7083175
    [Abstract] [Full Text] [Related]

  • 14. Thymidine as a kinetic and biochemical modulator of 1-beta-D-arabinofuranosylcytosine in human acute nonlymphocytic leukemia.
    Blumenreich MS, Chou TC, Andreeff M, Vale K, Clarkson BD, Young CW.
    Cancer Res; 1984 Feb 01; 44(2):825-30. PubMed ID: 6692380
    [Abstract] [Full Text] [Related]

  • 15. Kinetics and mechanism of the 1-beta-D-arabinofuranosylcytosine-induced potentiation of cis-diamminedichloroplatinum(II) cytotoxicity.
    Vadi H, Drewinko B.
    Cancer Res; 1986 Mar 01; 46(3):1105-9. PubMed ID: 3080232
    [Abstract] [Full Text] [Related]

  • 16. Detection of 1-beta-D-arabinofuranosylcytosine incorporation into DNA in vivo.
    Spriggs D, Robbins G, Ohno Y, Kufe D.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6532-6. PubMed ID: 3479246
    [Abstract] [Full Text] [Related]

  • 17. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA, Morgenstern B, Capizzi RL.
    Cancer Res; 1982 Jun 15; 42(6):2191-7. PubMed ID: 7074600
    [Abstract] [Full Text] [Related]

  • 18. Bromodeoxyuridine enhancement of 1-beta-D-arabinofuranosylcytosine metabolic activation and toxicity in HL-60 leukemic cells.
    Ross DD, Joneckis CC, Song TH, Wu RK.
    Cancer Res; 1988 Feb 01; 48(3):517-21. PubMed ID: 3335018
    [Abstract] [Full Text] [Related]

  • 19. Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside.
    Tanaka M, Kimura K, Yoshida S.
    Jpn J Cancer Res; 1985 Aug 01; 76(8):729-35. PubMed ID: 3930450
    [Abstract] [Full Text] [Related]

  • 20. Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux.
    Chan TC.
    Cancer Res; 1989 May 15; 49(10):2656-60. PubMed ID: 2713849
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 9.